2-Trifluoromethylthiazole-5-Carboxylic Acid Ethyl Este

In a cGMP intermediate suite equipped with a 100 L glass-lined reactor and a Propak-packed fractional distillation column, ethyl 2-trifluoromethylthiazole-5-carboxylate is routinely saponified to its free acid for subsequent incorporation into a series of investigational small-molecule kinase inhibitors targeting mutant EGFR and B-Raf^V600E. The ester (1.0 eq) is dissolved in THF/water (4:1 v/v) and treated with LiOH·H₂O (1.08 eq) at 0–5 °C under nitrogen over 4 h. In-process HPLC control (C18, 210 nm) is mandatory at 15-min intervals after the 2 h mark because the thiazole ring is susceptible to hydrolytic opening when residual hydroxide concentration exceeds 0.02 N and internal temperature drifts above 8 °C. Following pH adjustment to 2.8–3.0 with 10% citric acid at ≤5 °C, the resulting 2-trifluoromethylthiazole-5-carboxylic acid is isolated by centrifuge filtration, washed with chilled deionized water until conductivity drops below 50 µS/cm, and dried in a conical vacuum dryer at 40 °C and 10 mbar for 12 h. Residual Li⁺ is quantified by ion chromatography and routinely controlled at < 150 ppm, as even traces interfere with the HBTU-mediated coupling to 2-aminopyrimidine fragments later in the API assembly. The downstream API molecule, a type-II kinase inhibitor, derives its slow off-rate from the 2-trifluoromethylthiazole moiety’s occupation of a deep lipophilic back pocket; the carboxylic acid endpoint is further activated as the acid chloride using oxalyl chloride (1.2 eq) and DMF (0.05 eq) in dichloromethane at 20–25 °C before reacting with the pyrimidine amine building block. Residual solvents are controlled per ICH Q3C options 1 and 2; typically, THF is targeted below 720 ppm and DCM below 600 ppm. The entire process is documented under an exploratory IND batch record, with a certificate of analysis covering purity (≥98.0% area by HPLC), water content (≤0.5% by Karl Fischer), and heavy metals (≤20 ppm as per USP <231>).

What Determines the Acyl Chloride Formation Selectivity When the Ester is Activated for Agrochemical SDHI Constructs?

Succinate dehydrogenase inhibitor (SDHI) fungicides built on a 2-trifluoromethylthiazole core — often referred to by the generic scaffold ethyl 2-trifluoromethylthiazole-5-carboxamide — require the ester to be transformed into the acid chloride exclusively at the C5 carbonyl, while keeping the electron-deficient thiazole ring intact. When thionyl chloride (1.3 eq) is employed in toluene at reflux (110 °C), competing decarboxylation at the C5 position is observed at conversions above 92%, forming 2-trifluoromethylthiazole as a volatile byproduct that co-distills with toluene and triggers a false mass balance. Switching to oxalyl chloride with catalytic DMF (0.02 eq) in dichloromethane at 20 °C suppresses the decarboxylation path, but introduces a critical agitation dependency: at tip speeds below 1.5 m/s in a 50 L cylindrical reactor, micro-mixing gradients near the dip tube nozzle raise local oxalyl chloride concentration to 2.5× the stoichiometric ratio, causing ring chlorination at the 4-position as confirmed by ¹⁹F NMR signals at −63.2 ppm versus the expected −61.8 ppm for the intact CF₃ group. The preferred setup uses a 20 L Hastelloy C-22 stirred tank with a retreat-curve impeller at 250 rpm, adding the ester/TEA mixture to pre-charged oxalyl chloride over 90 min at −5 to 0 °C, followed by 2 h of post-reaction at 5 °C. The resulting acid chloride solution is consumed immediately (<30 min hold time) in a parallel 100 L reactor where it reacts with 2-amino-4-methylthiazole in the presence of powdered K₂CO₃ (2.2 eq) to form the target SDHI amide. The final agrochemical active ingredient, when milled to D₉₀ ≤5 μm and formulated as a 20% SC, shows a greenhouse EC₉₀ of 4.2 g a.i./ha against Botrytis cinerea isolates with H272Y mutation, a value directly correlated to residual acid chloride dimer content (controlled below 0.3 area%) which otherwise promotes phytotoxic chlorotic flecking on leaf margins. All in-process samples are quenched into excess morpholine and analyzed by LC-MS for the morpholine adduct of the acid chloride as the primary quantity indicator.

A distinct manufacturing campaign conducted in a multi-purpose kilo-lab with a 5 L jacketed vessel discards the acid chloride route altogether and instead couples the ethyl ester directly with 4-(trifluoromethyl)benzylamine via enzymatic aminolysis using immobilized Candida antarctica lipase B (CAL-B) on acrylic resin. The reaction is performed in methyl tert-butyl ether (MTBE) at 45 °C under a slight vacuum (800 mbar) to continuously remove ethanol cosolvent and shift equilibrium. Ester loading is maintained at 0.25 M, and the amine is fed semibatch-wise at 0.90 eq total to avert enzyme inhibition; fresh CAL-B beads are added at 20% w/w of ester after an initial 24 h activity drop monitored by drop in conversion from 78% to 62%. The direct amidation product, N-[4-(trifluoromethyl)benzyl]-2-trifluoromethylthiazole-5-carboxamide, precipitates as a white solid upon cooling the filtered reaction mass to −10 °C and is recrystallized from ethyl acetate/heptane (1:3) to obtain 99.2% purity with a residual ethanol limit below 50 ppm, meeting the specifications for a candidate veterinary anthelmintic under evaluation against haemonchosis in small ruminants. The synthesis elides the carboxylic acid isolation step, reduces organic waste volume by 42% relative to the acid chloride route, and is validated against ISO 14040 life-cycle inventory boundaries for gate-to-gate comparative process assessment.

Monitoring Thiazole Ring Integrity During Amine-Mediated Ester Interchange at Elevated Pressure

When ethyl 2-trifluoromethylthiazole-5-carboxylate is treated with aminoethanol derivatives to produce building blocks for β-lactamase inhibitors, the high basicity of aliphatic primary amines (pKa_BH+ ≈ 10.5) coupled with prolonged heating above 60 °C triggers a secondary decomposition cascade that releases fluoride ions and generates tars. In a validation run inside a 300 mL Parr 4560 mini-reactor, the ester (50 g, 223 mmol) and ethanolamine (15.0 g, 246 mmol) were sealed under 3 bar nitrogen and ramped to 75 °C over 30 min. At the 4 h mark, HPLC showed only 71% of the desired 2-trifluoromethylthiazole-5-carboxylic acid (2-hydroxyethyl)amide; the remainder consisted of a ring-opened dithioformamide adduct (12%) and a CF₃-defluorination product (8%) identified by ion-selective electrode measurement of liberated fluoride (up to 240 ppm in the quenched reaction mass). The process was modified by pre-neutralizing ethanolamine to its hydrochloride salt (pH 5.8 in methanol) and employing titanium(IV) isopropoxide (0.08 eq) as a Lewis acid co-catalyst; under the same thermal profile, conversion to the targeted amide reached 96% with ring-opened impurities suppressed to 1.2%. The amide intermediate is subsequently activated with methanesulfonyl chloride and treated with potassium thioacetate, then cyclized under Mitsunobu conditions to yield a tricyclic β-lactam intermediate that inhibits class A serine β-lactamases with an IC₅₀ of 8 nM in a nitrocefin hydrolysis assay. The ethyl ester’s trace presence in the final API (< 10 ppm) is analytically verified by headspace GC-MS according to USP <467> procedure A, because even sub-ppm residual ester can trans-esterify with a polyethylene glycol excipient during hot-melt extrusion of fixed-dose combination tablets.

For route scouting on a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) portfolio, the ethyl ester is reduced to 2-trifluoromethylthiazole-5-methanol with two parallel protocols evaluated for operational scalability. The first protocol charges a 20 L fixed-bed continuous hydrogenator (ThalesNano H-Cube Pro with a 70 mm catalyst cartridge) with Raney Ni and a 0.5 M solution of the ester in 2-propanol at 80 °C and 50 bar H₂; residence time is adjusted to 4.5 min to achieve 99.5% conversion. However, the strongly electron-withdrawing CF₃ group attenuates the catalyst surface’s electron density, leading to a steady leaching of nickel (8–15 ppm) into the product stream unless an in-line scavenger cartridge loaded with QuadraSil MP is placed downstream. The second protocol reduces the ester with sodium borohydride (2.2 eq) in anhydrous THF at 40 °C with rapid dropwise addition of methanol as a proton source; here, the limiting factor is foam formation during workup due to surfactant-like impurities originating from the ethyl ester’s previous-stage synthesis (trace ethyl 2-bromothiazole-5-carboxylate precursor). Foam is controlled by adding a Defoamer AC-104 silicone emulsion at 0.05% w/w relative to the organic phase before the first aqueous bicarbonate wash. The isolated thiazole methanol is converted via a Mitsunobu reaction with 4-cyanophenol to an NNRTI linker that shows sub-nanomolar affinity for the K103N mutant binding pocket. Throughout this intermediate’s life cycle, analytical compliance requires identity confirmation by quantitative ¹⁹F NMR (internal standard: 0.1 M sodium trifluoroacetate in D₂O) and differential scanning calorimetry (DSC) according to ASTM E793-06 to verify crystallinity reproducibility between batches.

In a dedicated synthesis of a topical dermatological preparation containing a 2-trifluoromethylthiazole-5-carboxylate-derived urea as the active pharmaceutical ingredient, the ester is first subjected to hydrazinolysis with hydrazine hydrate (1.05 eq) in ethanol at 10 °C to yield 2-trifluoromethylthiazole-5-carbohydrazide. The critical-to-quality (CTQ) attributes of this step are the minimization of the symmetric bis-acyl hydrazine dimer, formed via intermolecular attack of the product hydrazide on unreacted ester, which escalates when the hydrazine addition rate exceeds 0.15 eq/min and the solution temperature rises above 15 °C. The crude hydrazide is isolated by filtration, rinsed with cold 0.1 N NaHCO₃ to remove traces of acidic esters, and immediately reacted with an aryl isocyanate derivative in anhydrous 1,4-dioxane at 25 °C to assemble the urea. The final urea, after jet-milling to D₅₀ 2.0 μm and blending into a 1% w/w cetomacrogol emulsifying ointment base, demonstrates 12-fold higher epidermal layer retention at 24 h compared to the non-fluorinated thiazole analogue as measured by OECD TG 428 (in vitro skin penetration using Franz cells with human cadaver dermatomed skin). Process safety limits mandate the ester storage in polyethylene-lined fibre drums at ≤25 °C and ≤40% relative humidity because prolonged exposure to ambient moisture (> 60% RH) triggers a slow ester group hydrolysis that releases ethanol vapour and builds headspace pressure in sealed containers, requiring venting and retesting of water content before every production campaign.

When the Ester is Converted to a Thiazole Amidine for a Human Cytomegalovirus Terminase Inhibitor Candidate

Ethyl 2-trifluoromethylthiazole-5-carboxylate can be transformed into a substituted amidine by first converting the carboxylic acid derivative into a thioamide with Lawesson’s reagent, followed by S-alkylation and displacement with ammonia; however, the high electronegativity of the trifluoromethyl group retards the thiation at the C5 carbonyl sufficiently that standard stoichiometric Lawesson’s conditions (0.55 eq, toluene, 110 °C) stall at 65% conversion. Pushing the reaction to completeness requires a high-temperature sealed-tube approach (150 °C in a 100 mL ACE pressure tube, 48 h) in the presence of hexamethyldisiloxane (0.3 eq) as a P₂S₅ solubilizer, which yields the thioamide in 82% isolated yield after chromatography. The thioamide is then S-ethylated with methyltriflate in dichloromethane and the resulting methylthioimidate salt subjected to ammonia in methanol to provide the 2-trifluoromethylthiazole-5-carboximidamide, which shows potent inhibition of the HCMV terminase complex with an IC₉₀ of 0.7 nM in a nicking assay using purified pUL56-pUL89 proteins. Residual ethyl ester in the amidine intermediate is controlled below 0.1% because the ester outcompetes the amidine for binding at the pUL56 allosteric site when present at ≥0.5%, leading to a clinically significant shift in EC₅₀ from 0.2 µM to 4.6 µM in HCMV AD169 plaque reduction assays.